Patent: 7,381,560
✉ Email this page to a colleague
Summary for Patent: 7,381,560
Title: | Expression and use of anti-CD20 antibodies |
Abstract: | Disclosed are immunologically active antibodies directed against the CD20 antigen, as well as host cells comprising nucleic acid sequences encoding the light chains and heavy chains of immunologically active antibodies wherein the cell is capable of expressing and secreting an immunologically active chimeric anti-CD20 antibody and methods of using such host cells to make purified antibodies. The antibodies are useful for treating and diagnosing B cell disorders. |
Inventor(s): | Anderson; Darrell R. (Escondido, CA), Hanna; Nabil (Rancho Santa Fe, CA), Newman; Roland A. (San Diego, CA), Reff; Mitchell E. (San Diego, CA), Rastetter; William H. (Rancho Santa Fe, CA) |
Assignee: | Biogen Idec Inc. (Cambridge, MA) |
Application Number: | 09/911,692 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,381,560 |
Patent Claims: | see list of patent claims |
Details for Patent 7,381,560
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Acrotech Biopharma Llc | ZEVALIN | ibritumomab tiuxetan | Injection | 125019 | 02/19/2002 | ⤷ Try a Trial | 2012-11-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 7,381,560
Country | Patent Number | Estimated Expiration |
---|---|---|
Austria | 139900 | ⤷ Try a Trial |
Austria | 196606 | ⤷ Try a Trial |
Austria | 421335 | ⤷ Try a Trial |
Austria | 431158 | ⤷ Try a Trial |
Australia | 5603294 | ⤷ Try a Trial |
Australia | 688743 | ⤷ Try a Trial |
Bulgaria | 62386 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |